461 related articles for article (PubMed ID: 25448549)
1. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
2. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
3. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
4. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
5. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
6. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
7. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
Reddy LH; Ferreira H; Dubernet C; Mouelhi SL; Desmaele D; Rousseau B; Couvreur P
Anticancer Drugs; 2008 Nov; 19(10):999-1006. PubMed ID: 18827565
[TBL] [Abstract][Full Text] [Related]
8. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
[TBL] [Abstract][Full Text] [Related]
9. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
10. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
11. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues.
Caron J; Reddy LH; Lepêtre-Mouelhi S; Wack S; Clayette P; Rogez-Kreuz C; Yousfi R; Couvreur P; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2761-4. PubMed ID: 20363623
[TBL] [Abstract][Full Text] [Related]
12. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
13. Freeze-drying of squalenoylated nucleoside analogue nanoparticles.
Bildstein L; Hillaireau H; Desmaële D; Lepêtre-Mouelhi S; Dubernet C; Couvreur P
Int J Pharm; 2009 Nov; 381(2):140-5. PubMed ID: 19782881
[TBL] [Abstract][Full Text] [Related]
14. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
15. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
16. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
17. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
[TBL] [Abstract][Full Text] [Related]
18. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
[TBL] [Abstract][Full Text] [Related]
19. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
